221.22 -0.02 (-0.01%)
After hours: 4:00PM EDT
Previous Close | 217.54 |
Open | 218.88 |
Bid | 215.01 x 800 |
Ask | 231.09 x 800 |
Day's Range | 215.00 - 222.63 |
52 Week Range | 64.16 - 252.25 |
Volume | 116,604 |
Avg. Volume | 237,740 |
Market Cap | 6.174B |
Beta (5Y Monthly) | 1.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.19 |
Earnings Date | May 04, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 253.55 |
In this episode of Industry Focus: Wildcard, join Motley Fool contributor Brian Feroldi and host Emily Flippen as they talk about three companies trying to treat sleep apnea: ResMed (NYSE: RMD), Inspire Medical (NYSE: INSP), and Vivos Therapeutics (NASDAQ: VVOS). To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Today is Wednesday, March 24th, and I am your host, Emily Flippen.
MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2021 after the close of trading on Tuesday, May 4. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. Tuesday, May 4th @ 5:00 p.m. Eastern Time:Domestic: 877-407-0792International: 201-689-8263Conference ID: 13717525Webcast: http://public.viavid.com/index.php?id=143909 About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact:Bob YedidLifeSci Advisorsinspire@lifesciadvisors.com646-597-6989
Medical technology company Inspire Medical Systems received approval from the U.S. Food and Drug Administration (FDA) for the Inspire physician programmer platform. Inspire Medical Systems (INSP) is focused on minimally invasive solutions for treating patients with obstructive sleep apnea. The approved platform provides four major enhancements to the company’s existing product. These enhancements include guided workflows, a new programmer cable that allows for ease of use, and improved telemetry range. The platform enables interface with Inspire cloud and uploading patient reports. It also supports the further integration of Inspire cloud, which can potentially provide remote programming, a feature that is currently under development. Inspire Medical Systems’ President and Chief Executive Officer, Tim Herbert, said, “In addition to the recently announced approval for the Inspire two-cision procedure, the launch of our new physician programmer platform further demonstrates our long-term commitment to patients through Inspire’s continued investment in our innovative technologies.” Herbert added, “The new Inspire physician programmer platform provides multiple key benefits for physicians when managing their patients’ sleep apnea treatment with Inspire therapy.” (See Inspire Medical stock analysis on TipRanks) Last month, Oppenheimer analyst Suraj Kalia reiterated a Hold rating on the stock without assigning a price target. Kalia said, “Inspire is the first company to commercialize hypoglossal nerve stimulation (HGNS) to pull the tongue forward, therefore improving airway patency in obstructive sleep apnea (OSA) patients.” Turning to the rest of the Street, the stock has a Strong Buy consensus rating alongside an average analyst price target of $253.25 (22.3% upside potential), based on 6 Buys and 2 Holds. Shares have gained about 226.2% over the past year. Related News: TEGNA Bumps Up Quarterly Dividend By 36% Palomar To Buy Back $40M In Stock; Shares Gain After-Hours Globe Life Ramps Up Quarterly Dividend By 5.3% More recent articles from Smarter Analyst: Campbell Soup To Sell Plum Organics Brand KKR Snaps Up The Exchange In San Francisco For $1B Walgreens Rises After 2Q Profit Win, Lifts Guidance Dave & Buster’s Paces Past 2Q Estimates Despite COVID-19 Headwinds